If administered early, gene therapy has the potential to change the medical history of children born with metachromatic ...

Mast cells, a major target for masitinib ... and this number could reach 400,000 by 2050 [4]. Sickle cell disease affects over 100,000 children and adults in the United States. In France, ...

According to the American College of Allergy Asthma and Immunology, nearly one in three U.S. adults report having a seasonal ...

health.wa.gov.au Background Cross-sectional studies implicate neutrophilic inflammation and pulmonary infection as risk factors for early structural lung disease in infants and young children with ...

Although clear areas of overlap are known to exist between mast cell disorders and eosinophilia, it is seemingly easier to navigate each of these disease entities separately—that is, to address mast ...

Mast cell activation syndrome, or disease (MCAS), is a condition that causes mast cells to release these substances too frequently, resulting in severe allergic reactions. After detecting an ...

This achievement opens new horizons and offers innovative treatment for patients suffering from sickle cell disease (SCD) and transfusion dependent beta-thalassemia (TDT), positioning Abu Dhabi as a ...

“Separately or in association, these 2 tests can help identify mast cell involvement in disease, confirm diagnosis, and guide therapeutic management,” they noted. “The field is the focus of a ...

Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, potentially opening a path to new treatments for a condition that kills 80% of ...

Inc., a clinical-stage company developing advanced cell therapies to treat eye diseases. Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage ...

Chronic Kidney Disease (CKD ... of creating abnormal cells. Chronic exposure to toxins is also a causative factor. The longer a child has CKD, the greater the likelihood of developing cancer at a ...

The potential target, the FLT1 gene, contributes to the production of a protein, fetal hemoglobin, whose presence is already known to improve the lifespan of people with sickle cell disease.